VEGFA and neoplasm: There were no statistical differences between the two groups in terms of age, gender, ECOG score, tumor size, IMDC risk group, number of previous treatment lines, first-line anti-VEGF therapy, or metastasis sites (p = 0.137, p = 0.608, p = 0.100, p = 0.376, p = 0.185, p = 0.776, p = 0.350, and p = 0.608, respectively).